NEW YORK (360Dx) – Antibiotic susceptibility testing firm Selux Diagnostics announced today it has signed a contract with the Biomedical Advanced Research and Development Authority for up to $45 million.
The Boston-based firm will receive $9.3 million upfront to fund a clinical trial for its NGP next-generation phenotyping platform. SeLux is eligible for an additional $36 million, contingent on it meeting certain milestones, for the development of a second-generation rapid sepsis diagnostic platform, it said.
BARDA is a division of the US Department of Health and Human Services.
SeLux said that its NGP Platform can provide results that allow physicians to determine appropriate antibiotics up to three days faster than with current technologies. According to the company's website, its Universal Synthetic Amplifier technology delivers antimicrobial susceptibility testing results in four hours. Because the technology leverages standard equipment, adoption is simple, it added.